Form 13-F position report

KINNATE BIOPHARMA INC

Reported by STATE STREET CORPORATION

KNTE CUSIP 49705R105 Manager CIK 0000093751

Reported 0 shares, down 61,959 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q1 2024
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 13 Through Q1 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 6892000
2022-03-31 4765000
2022-06-30 5703000
2022-09-30 5575000
2022-12-31 2825410
2023-03-31 2914881
2023-06-30 187736
2023-09-30 86743
2023-12-31 146843
2024-03-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

10 quarters
Quarterly reported position history for KINNATE BIOPHARMA INC held by STATE STREET CORPORATION.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q1 2024 Reduced 0 -61,959 (-100.0%) 0 $0 2024-05-15
Q4 2023 Unchanged 61,959 0 (0.0%) < 0.01% $146,843 2024-02-14
Q3 2023 Unchanged 61,959 0 (0.0%) < 0.01% $86,743 2023-11-14
Q2 2023 Reduced 61,959 -404,422 (-86.7%) < 0.01% $187,736 2023-08-14
Q1 2023 Added 466,381 +3,199 (0.7%) < 0.01% $2,914,881 2023-05-15
Q4 2022 Reduced 463,182 -3,339 (-0.7%) < 0.01% $2,825,410 2023-02-14
Q3 2022 Added 466,521 +14,243 (3.1%) < 0.01% $5,575,000 2022-11-15
Q2 2022 Added 452,278 +29,124 (6.9%) < 0.01% $5,703,000 2022-08-15
Q1 2022 Added 423,154 +34,224 (8.8%) < 0.01% $4,765,000 2022-05-16
Q4 2021 Added 388,930 +56,355 (16.9%) < 0.01% $6,892,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

77 managers reported KINNATE BIOPHARMA INC for Q1 2024.

Managers reporting KINNATE BIOPHARMA INC in Q1 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Foresite Capital Management IV LLC Unchanged 9,671,643 0 13.0% $25,726,570 14 qtrs
ORBIMED ADVISORS LLC Unchanged 8,009,729 0 0.39% $21,305,879 14 qtrs
Foresite Capital Management V LLC Unchanged 3,525,957 0 8.8% $9,379,046 14 qtrs
Lynx1 Capital Management LP Reduced 1,981,106 -15,900 1.36% $5,269,742 9 qtrs
VIKING GLOBAL INVESTORS LP Unchanged 1,820,462 0 0.02% $4,842,429 14 qtrs
VANGUARD GROUP INC Added 1,076,789 +33,879 < 0.01% $2,864,259 14 qtrs
DELTEC ASSET MANAGEMENT LLC New 1,039,800 +1,039,800 0.55% $2,765,868 1 qtr
TANG CAPITAL MANAGEMENT LLC Reduced 977,626 -1,624,021 0.27% $2,600,485 2 qtrs
ACADIAN ASSET MANAGEMENT LLC Added 964,881 +134,388 < 0.01% $2,565,000 8 qtrs
RENAISSANCE TECHNOLOGIES LLC Added 887,740 +312,761 < 0.01% $2,361,000 12 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2024
Filed
May 15, 2024
Filing type
13F-HR
Position type
COM

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.